bêta
IA Trial Radar
L'essai clinique NCT06421740 (REACH-AD) pour Dermatite atopique est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China (REACH-AD) 1 000 Données vie réelle Adolescent Observationnel

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT06421740 (REACH-AD) est une étude observationnel pour Dermatite atopique. Son statut actuel est : en recrutement. L'étude a débuté le 7 juin 2024 et vise à recruter 1 000 participants. Dirigée par AbbVie, l'étude devrait être terminée d'ici le 1 juin 2026. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 12 mars 2026.
Résumé succinct
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin.

Upadacitinib is an approved drug for treating AD. Approximately 1000 adolescents and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in up to 40 sites in China.

Participants will receive oral upadacitinib tablets as prescribed by their ph...

Afficher plus
Titre officiel

REal-world Utilization and Treatment Target ACHievement With Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis in China

Pathologies
Dermatite atopique
Autres identifiants de l'étude
  • REACH-AD
  • P24-965
Numéro NCT
NCT06421740
Date de début (réel)
2024-06-07
Dernière mise à jour publiée
2026-03-12
Date de fin (estimée)
2026-06
Inscription (estimée)
1 000
Type d'étude
Observationnel
Statut
En recrutement
Mots clés
Upadacitinib
Rinvoq
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
Upadacitinib
Participants will receive upadacitinib as prescribed by their physician according to local label.
N/A
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Number of participants with a dose change
Dose change includes: Changed dose, dose escalation or dose tapering.
12 Months
Number of participants with Upadacitinib drug compliance
The participants missed medication, regardless of reason, or incompliance with the prescription as per medical advice are to be recorded in the eDiary, choosing the reason: "Forgot, Self-reduction of medication, interruption because of AE, interruption not due to safety/tolerability, for other reasons". If no eDiary entries are found within 30 days before the visit, the participant will need to complete the following question in ePRO: timely Upadacitinib intake per medical advice in past 30 days (yes/no); if "no", days-off-drug, intentionally or accidentally, and if "intentionally", reason for incompliance with medical prescription.
12 Months
Number of participants with interruption or permanent discontinuation
Interruption: Upadacitinib is temporarily interrupted due to atopic dermatitis disease condition, economic, tolerance, AE, or personal reasons, and the investigator considers there is still possibility of Upadacitinib re-initiating within the patient's study follow-up period. Discontinuation: Upadacitinib is permanently discontinued for safety or any other reasons, and the investigator considers Upadacitinib will not be used again, at least within the participant's study follow-up period.
12 Months
Assistant à la participation
Critères d'éligibilité

Âges éligibles
Enfant, Adulte, Adulte âgé
Âge minimum
12 Years
Sexes éligibles
Tous
  • Adolescents (body weight >= 40 kg at the Baseline Visit for patients between >= 12 and < 18 years of age) and adults at the time of enrollment.
  • Clinical diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
  • UPA treatment is indicated for AD and prescribed as per Chinese label / SmPC.
  • The decision to prescribe UPA is made prior to and independent of study participation.
  • The participant should not be treated with UPA prior to this study.
  • Participants who are willing and able to participate in the collection of patient-reported data, including ePROs and eDiary via apps.
  • The participant (legal representative for adolescents) voluntarily signed an informed consent before any study-related activities are conducted.

  • The participant is currently participating in interventional research (not including noninterventional study, observational study, or registry participation).
  • Any circumstances that the investigator believes may limit the patient's participation and compliance with study procedures.
AbbVie logoAbbVie338 essais cliniques actifs à explorer
Contact central de l'étude
Contact: Judy Yu, [email protected]
38 Centres de l'étude dans 1 pays

Beijing Municipality

Beijing Anzhen Hospital /ID# 273443, Beijing, Beijing Municipality, 100029, China
Actif, ne recrute pas
China-Japan Friendship Hospital /ID# 274778, Beijing, Beijing Municipality, 100029, China
Actif, ne recrute pas
Peking University First Hospital /ID# 274865, Beijing, Beijing Municipality, 100034, China
Actif, ne recrute pas
Peking Unversity Third hospital /ID# 274864, Beijing, Beijing Municipality, 100191, China
Actif, ne recrute pas
Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 264193, Beijing, Beijing Municipality, 100730, China
Actif, ne recrute pas

Fujian

The First Affiliated Hospital Of Fujian Medical University /ID# 268210, Fuzhou, Fujian, 350005, China
Actif, ne recrute pas
Changgeng Hospital /ID# 268209, Xiamen, Fujian, 361022, China
En recrutement

Guangdong

Guangzhou Dermatology Hospital /ID# 271684, Guangzhou, Guangdong, 510095, China
Actif, ne recrute pas
The Fifth Affiliated Hospital Of Sun Yat-Sen University /ID# 268618, Zhuhai, Guangdong, 519000, China
En recrutement

Hainan

Hainan Fifth People's Hospital /ID# 269747, Hainan, Hainan, 200000, China
En recrutement

Hebei

Hebei Engineering University Affiliated Hospital /ID# 268660, Handan, Hebei, 200000, China
En recrutement

Heilongjiang

The Second Affiliated Hospital Of Harbin Medical University /ID# 270872, Harbin, Heilongjiang, 150001, China
En recrutement

Henan

People's Hospital of Henan Province /ID# 269744, Zhengzhou, Henan, 450003, China
En recrutement

Hubei

Wuhan Integrated TCM & Western Medicine Hospital（Wuhan No.1 Hospital) /ID# 272374, Wuhan, Hubei, 430022, China
En recrutement
Tongji Hospital /ID# 269745, Wuhan, Hubei, 430030, China
En recrutement

Hunan

Xiangya Hospital Central South University /ID# 272373, Changsha, Hunan, 410008, China
Actif, ne recrute pas

Jiangsu

Nanjing Drum Tower Hospital /ID# 268616, Nanjing, Jiangsu, 210008, China
En recrutement
Affiliated Hospital Of Nantong University /ID# 269743, Nantong, Jiangsu, 226001, China
En recrutement
The First Affiliated Hospital of Soochow University /ID# 269742, Suzhou, Jiangsu, 215006, China
En recrutement
The Affiliated Hospital of Xuzhou Medical College /ID# 268208, Xuzhou, Jiangsu, 221006, China
En recrutement

Liaoning

Dalian Dermatosis Hospital /ID# 272495, Dalian, Liaoning, 116041, China
Actif, ne recrute pas
The People's Hospital of Liaoning Province /ID# 268206, Shenyang, Liaoning, 110016, China
Terminé

Shandong

Shandong Provincial Hospital /ID# 268661, Jinan, Shandong, 250001, China
En recrutement
Jining Medical University - Affiliated Hospital /ID# 270873, Jining, Shandong, 272029, China
En recrutement
Weifang People'S Hospital /ID# 268659, Weifang, Shandong, 261041, China
En recrutement

Shanghai Municipality

Ruijin Hospital /ID# 268658, Shanghai, Shanghai Municipality, 200025, China
Actif, ne recrute pas
Huashan Hospital Of Fudan University /ID# 270277, Shanghai, Shanghai Municipality, 200040, China
En recrutement
Shanghai Sixth People'S Hospital /ID# 268617, Shanghai, Shanghai Municipality, 200233, China
En recrutement
Shanghai Skin Disease Hospital /ID# 268657, Shanghai, Shanghai Municipality, 200443, China
En recrutement

Sichuan

West China Hospital of Sichuan University /ID# 268313, Chengdu, Sichuan, 610041, China
Actif, ne recrute pas
Sichuan Provincial People's Hospital /ID# 268314, Chengdu, Sichuan, 610072, China
En recrutement
The Affiliated Hospital Of Southwest Medical University /ID# 268207, Luzhou, Sichuan, 646600, China
En recrutement

Xinjiang

People's Hospital of Xinjiang Uygur Autonomous Region /ID# 269746, Ürümqi, Xinjiang, 830001, China
En recrutement

Yunnan

The First Affiliated Hospital of Kunming Medical College /ID# 273451, Kunming, Yunnan, 650032, China
En recrutement

Zhejiang

Zhejiang Provincial Hospital of Chinese Medicine /ID# 268613, Hangzhou, Zhejiang, 310006, China
En recrutement
Ningbo No.6 hospital /ID# 268315, Ningbo, Zhejiang, 315040, China
En recrutement
Taizhou Central Hospital /ID# 268211, Taizhou, Zhejiang, 318000, China
En recrutement
Zhuji People'S Hospital /ID# 268614, Zhuji, Zhejiang, 315000, China
En recrutement